

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED

北京同仁堂國藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3613)

ANNOUNCEMENT

**FINANCIAL INFORMATION ANNOUNCEMENT OF TONG REN TANG
TECHNOLOGIES FOR THE THIRD QUARTER OF 2022**

The announcement is made by Beijing Tong Ren Tang Chinese Medicine Company Limited (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Company notes that Tong Ren Tang Technologies Co. Ltd. (“**Tong Ren Tang Technologies**”) published an announcement today in relation to certain unaudited financial information of Tong Ren Tang Technologies and its subsidiaries for the nine months ended 30 September 2022. For detailed information, please refer to the announcement published by Tong Ren Tang Technologies on the website of the Stock Exchange at www.hkexnews.hk.

Tong Ren Tang Technologies is the controlling shareholder (as defined in the Listing Rules) of the Company as at the date of the announcement. Tong Ren Tang Technologies (stock code: 1666) is listed on the Main Board of the Stock Exchange.

Separately, the controlling shareholder of Tong Ren Tang Technologies, Beijing Tong Ren Tang Company Limited (“**Tong Ren Tang Ltd.**”), will announce its unaudited results for the nine months ended 30 September 2022 on the Shanghai Stock Exchange on or before 31 October 2022. If you wish to obtain further information, please visit the website of Tong Ren Tang Ltd..

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
Beijing Tong Ren Tang
Chinese Medicine Company Limited
Ding Yong Ling
Chairman

Hong Kong, 26 October 2022

As at the date of this announcement, the composition of the Board is as follows:

Executive Directors:

Ms. Ding Yong Ling (*Chairman*)
Mr. Chen Fei
Ms. Lin Man
Ms. Feng Li

Independent Non-executive Directors:

Mr. Tsang Yok Sing, Jasper
Mr. Zhao Zhong Zhen
Mr. Chan Ngai Chi